Altmetric

Management of fibrosing interstitial lung diseases

File Description SizeFormat 
Maher-Wuyts2019_Article_ManagementOfFibrosingInterstit.pdfPublished version364.83 kBAdobe PDFView/Open
Title: Management of fibrosing interstitial lung diseases
Authors: Maher, TM
Wuyts, W
Item Type: Journal Article
Abstract: A proportion of patients with interstitial lung diseases (ILDs), including the ILDs that are commonly associated with autoimmune diseases, develop a progressive fibrosing phenotype characterised by worsening of lung function, dyspnoea and quality of life, and early mortality. No drugs are approved for the treatment of ILDs other than idiopathic pulmonary fibrosis (IPF). At present, immunomodulatory medications are the mainstay of treatment for non-IPF ILDs. However, with the exception of systemic sclerosis-associated ILD, the evidence to suggest that immunosuppression may preserve lung function in patients with these ILDs comes only from retrospective, observational, or uncontrolled studies. In this article, we review the evidence for the treatments currently used to treat ILDs associated with autoimmune diseases and other ILDs and the ongoing trials of immunosuppressant and antifibrotic therapies in patients with these ILDs.
Issue Date: 1-Jul-2019
Date of Acceptance: 1-May-2019
URI: http://hdl.handle.net/10044/1/72971
DOI: https://dx.doi.org/10.1007/s12325-019-00992-9
ISSN: 0741-238X
Publisher: Springer (part of Springer Nature)
Start Page: 1518
End Page: 1531
Journal / Book Title: Advances in Therapy
Volume: 36
Issue: 7
Copyright Statement: © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pharmacology & Pharmacy
Research & Experimental Medicine
Collagen diseases
Immunosuppression
Interstitial lung disease
Respiratory
Rheumatic diseases
Treatment
IDIOPATHIC PULMONARY-FIBROSIS
STEM-CELL TRANSPLANTATION
SYSTEMIC-SCLEROSIS
INTRAVENOUS CYCLOPHOSPHAMIDE
MYCOPHENOLATE-MOFETIL
ORAL AZATHIOPRINE
TERM OUTCOMES
DOUBLE-BLIND
NINTEDANIB
RITUXIMAB
Collagen diseases
Immunosuppression
Interstitial lung disease
Respiratory
Rheumatic diseases
Treatment
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pharmacology & Pharmacy
Research & Experimental Medicine
Collagen diseases
Immunosuppression
Interstitial lung disease
Respiratory
Rheumatic diseases
Treatment
IDIOPATHIC PULMONARY-FIBROSIS
STEM-CELL TRANSPLANTATION
SYSTEMIC-SCLEROSIS
INTRAVENOUS CYCLOPHOSPHAMIDE
MYCOPHENOLATE-MOFETIL
ORAL AZATHIOPRINE
TERM OUTCOMES
DOUBLE-BLIND
NINTEDANIB
RITUXIMAB
General Clinical Medicine
1115 Pharmacology and Pharmaceutical Sciences
Publication Status: Published
Online Publication Date: 2019-05-22
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons